Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs.
The cellular mechanism of action of the cannabimimetic drugs is examined using cultured cells. In membranes from N18TG2 neuroblastoma cells and the neuroblastoma X glioma hybrid cells, NG108-15, the psychoactive cannabinoid drugs and their nantradol analogs could inhibit adenylate cyclase activity. This response was not observed in either the soluble adenylate cyclase from rat sperm or membrane-bound adenylate cyclases from C6 glioma or S49 lymphoma cells. This cellular selectivity provides further evidence for the existence of specific receptors for the cannabimimetic compounds. Receptor-mediated inhibition of adenylate cyclase requires the presence of a guanine nucleotide-binding protein complex, Gi. Gi can be functionally inactivated as a result of an ADP-ribosylation modification catalyzed by pertussis toxin. The present study demonstrates that pertussis toxin treatment of cells abolished the cannabimimetic response in intact cells and in membranes derived therefrom. The action of pertussis toxin required NAD+ as substrate for in vitro modification of neuroblastoma membranes. Furthermore, pertussis toxin was able to catalyze the labeling of a neuroblastoma membrane protein in vitro using [32P] NAD+ under conditions similar to those by which attenuation of the cannabimimetic inhibition of adenylate cyclase could be demonstrated. This evidence demonstrates the requirement for a functional Gi in the action of cannabimimetic drugs.
Howlett
A C
AC
Qualy
J M
JM
Khachatrian
L L
LL
D000246:Adenosine Diphosphate Ribose / Q000378:metabolism; D037361:Adenylate Cyclase Toxin; D000067956:Adenylyl Cyclase Inhibitors; D000818:Animals; D002186:Cannabinoids / Q000494:pharmacology*; D002217:Carbachol / Q000494:pharmacology; D002478:Cells, Cultured; D000242:Cyclic AMP / Q000378:metabolism; D013759:Dronabinol / Q000494:pharmacology; D019204:GTP-Binding Proteins / Q000502:physiology*; D005910:Glioma / Q000201:enzymology; D006822:Hybrid Cells; D008223:Lymphoma / Q000201:enzymology; D008345:Manganese / Q000494:pharmacology; D008565:Membrane Proteins / Q000378:metabolism; D009020:Morphine / Q000494:pharmacology; D009243:NAD / Q000378:metabolism; D009447:Neuroblastoma / Q000201:enzymology; D037342:Pertussis Toxin; D051381:Rats; D012633:Secretin / Q000494:pharmacology; D013004:Somatostatin / Q000494:pharmacology; D010566:Virulence Factors, Bordetella / Q000494:pharmacology
D037361:Adenylate Cyclase Toxin; D000067956:Adenylyl Cyclase Inhibitors; D002186:Cannabinoids; D008565:Membrane Proteins; D010566:Virulence Factors, Bordetella; D009243:NAD; D012633:Secretin; D000246:Adenosine Diphosphate Ribose; D008345:Manganese; D013004:Somatostatin; D009020:Morphine; D013759:Dronabinol; D002217:Carbachol; D000242:Cyclic AMP; D037342:Pertussis Toxin; D019204:GTP-Binding Proteins